Prosecution Insights
Last updated: November 04, 2026

Stelexis Therapeutics LLC

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Stelexis Therapeutics LLC maintains a company patent portfolio focused within the Biotechnology & Pharmaceuticals technology area. This specific sector often involves complex regulatory and technical hurdles, yet the current portfolio shows a highly concentrated prosecution footprint. There is currently 1 pending office action across the entire portfolio, indicating a narrow window of active engagement with the patent office at this time.

The prosecution is handled by 1 distinct examiner working within 1 distinct art unit. This total concentration suggests that the company's current patenting efforts are focused on a singular technological niche or a very specific set of claims. KAUFMAN, CLAIRE M is identified as the busiest examiner for this portfolio. This individual is responsible for the 1 pending office action currently on record.

Having 1 distinct examiner manage the entirety of the pending work allows for a consistent dialogue between the applicant and the USPTO. Because the busiest examiner pending count is 1, the workload is not distributed but centralized. This structure means that the outcome of the current Biotechnology & Pharmaceuticals filings depends entirely on the interactions with this single official.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KAUFMAN, CLAIRE M 1 63.3% +50.7%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18019164 IL-8 ANTIBODIES AND METHODS OF USE THEREOF KAUFMAN, CLAIRE M —

Top Art Units

Art UnitApps
1674 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18019164 IL-8 ANTIBODIES AND METHODS OF USE THEREOF KAUFMAN, CLAIRE M 1674 §112 Non-Final OA — Pending Feb 01, 2023

Managing Stelexis Therapeutics LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Stelexis Therapeutics LLC have?

Stelexis Therapeutics LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Stelexis Therapeutics LLC applications?

Claire M Kaufman has the most, with 1 of Stelexis Therapeutics LLC's pending office actions.

What technology area are Stelexis Therapeutics LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month